Emerging therapeutic strategies targeting CD4+ T cells include blockade of IL-17 signaling to counteract Th17-driven tumor progression, and the development of CD4+ T cell-based vaccines and adoptive T cell therapies. This evidence concerns the gene CD4 and neoplasm.